A clinical-stage T-cell reprogramming company advancing a pipeline of cell therapies for patients with solid tumors
201 - 500
π° $493M Series C on 2020-03
August 8
π’ In-office - San Francisco
π΅ $230k - $255k / year
β° Full Time
π΄ Lead
βοΈ Operations
π H1B Visa Sponsor